Day: July 30, 2020

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.“We continue to work towards completion of our planned merger with Adicet Bio, which is expected to close in the second half of 2020,” said Chen Schor, Co-Founder, President and CEO of resTORbio. “We believe that the newly combined company will be well positioned to generate greater shareholder value through the continued efforts of developing and ultimately bringing to market off-the-shelf allogeneic gamma delta T cell therapies for oncology and other diseases.”Recent Corporate HighlightsEntered into...

Series  RIKV 21 0215Settlement Date  08/04/2020Total Amount Allocated (MM)  14,500All Bids Awarded At (Price / Simple interest)  99.381 / 1.150Total Number of Bids Received  18Total Amount of All Bids Received (MM)  29,600Total Number of Successful Bids  14Number of Bids Allocated in Full  14Lowest Price / Highest Simple Interest Allocated  99.381 / 1.150Highest Price / Lowest Simple Interest Allocated  99.515 / 0.900Lowest Price / Highest Simple Interest Allocated in Full  99.381 / 1.150Weighted Average of Successful Bids (Price/Simple Interest)  99.407 / 1.101Best Bid (Price / Simple Interest)  99.515 / 0.900Worst Bid (Price / Simple Interest)  99.301 / 1.300Weighted Average of All Bids Received (Price / Simple Interest)  99.377 / 1.157Percentage Partial Allocation (Approximate)  100.00...

Flokkur  RIKV 21 0215Greiðslu-og uppgjörsdagur  04.08.2020Samþykkt tilboð að nafnverði (m.kr.)  14.500Samþykkt (verð / flatir vextir)  99,381 / 1,150Fjöldi innsendra tilboða  18Upphæð móttekinna tilboða að nafnverði (m.kr.)  29.600Fjöldi samþykktra tilboða  14Fjöldi samþykktra tilboða úthlutað að fullu  14Lægsta úthlutaða verð / Hæstu úthlutuðu flötu vextir  99,381 / 1,150Hæsta úthlutaða verð / Lægstu úthlutuðu flötu vextir  99,515 / 0,900Lægsta verð / Hæstu flötu vextir úthlutaðir að fullu  99,381 / 1,150Vegið meðaltal samþykktra tilboða (verð / flatir vextir)  99,407 / 1,101Besta tilboð (verð / flatir vextir)  99,515 / 0,900Versta tilboð (verð / flatir vextir)  99,301 / 1,300Vegið meðaltal innsendra tilboða (verð / flatir vextir)  99,377 / 1,157Hlutfall samþykktra tilboða sem tekin eru að...

– Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications –NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration (FDA) in July 2018 under the name TPOXX®.  The MAA was filed under the centralized application process, which, upon approval, and will enable sales and marketing of oral tecovirimat in all EU member states, as well as Norway, Iceland, and Liechtenstein.  SIGA has filed its application for oral tecovirimat seeking a broader label indication covering...

VANCOUVER, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that the Company has been invited to participate in the Canaccord Genuity 40th Annual Global Growth Conference August 11-13th, 2020. CloudMD’s CEO, Dr. Essam Hamza, will be presenting virtually on Wednesday, August 12th at 10am ET in track 11. The Company will also be participating in one-on-one investor meetings.Dr. Essam Hamza, CEO of CloudMD commented, “With the significant changes in the healthcare sector, namely the growth in telehealth, we are looking forward to presenting CloudMD’s revolutionary healthcare delivery platform. Equally important,...

Revenue     °     91.6% increase in Q2 2020 revenue to $112.2 million     °    54.8% increase in H1 2020 revenue to $210.1 millionNet Cash from Operating Activities     °    $50.7 million in H1 2020$     °    20.2 million in Q2 2020Adjusted EBITDA     °    228.8% increase in Q2 2020 Adjusted EBITDA to $72.7 million     °    103.5% increase in H1 2020 Adjusted EBITDA to $129.0 millionLiquidation of Navios Europe II Inc.     °    $37.7 million receivables transformed into cash and steel value$92.9 million refinancing for six product tankers     °    Maturities extended through 2027Fleet Renewal:     °    Option for 4th VLCC newbuilding under bareboat charter exercised in Q2 2020Returning capital to stockholders:     °    Quarterly dividend: $0.30 per shareMONACO, July 30, 2020 (GLOBE NEWSWIRE) — Navios Maritime Acquisition Corporation...

JSC Olainfarm hereby provides a comment to certain statements mentioned in an article in newspaper Diena.Chairperson of the Board of JSC Olainfarm Jeroen Weites:“These are rumours. JSC Olainfarm is not currently planning on selling any daughter companies, and no such decisions have been made. Given the Olainfarm Group’s ambitious growth plans and the new five-year business strategy that is being developed, it was important for the company to understand the current asset value of its daughter companies. JSC Olainfarm has signed an agreement with one of the auditors of the Big Four, who has been instructed to perform an asset evaluation. It has no other underlying causes. In addition, JSC Olainfarm daughter companies have recently undergone changes in the Management Board, and both Latvijas Aptieka Ltd and Tonus Elast Ltd have new Chairpersons...

Ar šo AS “Olainfarm” sniedz komentāru par laikrakstā Diena izteiktajiem apgalvojumiemAS “Olainfarm” valdes priekšsēdētājs Jerūns Veitess (Jeroen Weites):“Tās ir baumas. AS “Olainfarm” šobrīd neplāno iespēju pārdot meitas uzņēmumus, un nekādi šādi lēmumi nav pieņemti. Ņemot vērā “Olainfarm” grupas ambiciozos izaugsmes plānus un jaunu piecgades biznesa stratēģiju, kas tiek izstrādāta, uzņēmumam bija svarīgi saprast meitas uzņēmumu pašreizējo aktīvu vērtību. AS “Olainfarm” ir noslēgusi līgumu ar vienu no lielā četrinieka auditoriem, kam dots uzdevums veikt aktīvu novērtējumu. Tam nav citi zemūdens akmeņi. Turklāt “Olainfarm” meitas uzņēmumos pavisam nesen ir veiktas izmaiņas valdē, gan SIA “Latvijas Aptieka”, gan SIA “Tonus Elast” ir jauni valdes priekšsēdētāji, apliecinot izaugsmes plānus. Skatīt paziņojumu šeit:https://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=949269&messageId=1195981.Aicinām...

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic PainSale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract CancerSubstantial Debt Reduction, Including Full Repayment of Secured LoanTHE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development.  In that regard:Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of...

Fort Worth, TX, July 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — ADM Endeavors, Inc. (OTCQB: ADMQ) is pleased to announce that its wholly owned subsidiary, Just Right Products, Inc., has been awarded by the Tarrant County Commissioner’s Court the annual contract as the primary vendor for work uniforms for Tarrant County, Texas.Marc Johnson, CEO of ADM Endeavors, stated that the 1-year contract commenced on July 1, 2020 and should provide a projected revenue in excess of $50,000. Mr. Johnson explained that since being awarded this contract, the Company is now on a bid list for an additional 525 government entities throughout the State of Texas that can participate under this contract and “piggyback” on to the pricing provided by the Company in this contract. This added feature to the award provides the Company significant...